Each tablet of Equagesic, for oral administration, contains 200 mg meprobamate and 325 mg aspirin.
As an adjunct in the short-term treatment of pain accompanied by tension and/or anxiety in patients with musculoskeletal disease. Clinical trials have demonstrated that in these situations relief of pain is somewhat greater than with aspirin alone.† Equagesic is not intended for use longer than 10 days.
Media Articles Related to Equagesic (Meprobamate / Aspirin)
More resilient people tend to have a higher pain tolerance
Source: Anxiety / Stress News From Medical News Today [2014.09.13]
Resilience, a person's ability to overcome adverse circumstances, is the main quality associated with pain tolerance among patients and their adjustment to chronic pain.
Avoiding Pain Management Prosecutions
Source: Medscape NeurologyHeadlines [2014.09.12]
The key to staying out of court, says an attorney with years of experience in the field, is keeping up-to-date documentation.
Medscape Medical News
International Conference and Exhibition on Pain Medicine,¬†June 08-10, 2015, Chicago
Source: Conferences News From Medical News Today [2014.09.12]
OMICS Group is pleased to invite you to participate in the¬†International Conference and Exhibition on Pain Medicine¬†during¬†June 08-10, 2015¬†at¬†Chicago, USA.
Groundbreaking study reveals best positions for sex for men who have back pain
Source: Sexual Health / STDs News From Medical News Today [2014.09.12]
Contrary to popular belief, spooning is not always the best sex position for those with a bad back, according to new research from the University of Waterloo.
OncoBriefs: New Myeloma Standard? Robotics and Pain (CME/CE)
Source: MedPageToday.com - medical news plus CME for physicians [2014.09.12]
(MedPage Today) -- Patients with newly diagnosed multiple myeloma lived longer and had significantly slower disease progression with a new two-drug regimen than with a long-time, standard three-drug regimen, a randomized trial showed.
Page last updated: 2014-09-13